Cantor Fitzgerald analyst Louise Chen maintained a Hold rating on Teva Pharma (NYSE: TEVA) today and set a price target of $25. The company’s shares opened today at $23.64.
Chen commented:
“. We are raising our 12-month PT for TEVA shares to $25 from $18. The increase in our PT is driven by multiple expansion This is supported by, stable generic drug pricing, solid execution of TEVA’s stated business objectives, and the expected approval of fremanezumab later this year.”
According to TipRanks.com, Chen has currently no stars on a ranking scale of 0-5 stars, with an average return of -3.3% and a 42.9% success rate. Chen covers the Healthcare sector, focusing on stocks such as Melinta Therapeutics Inc, Aclaris Therapeutics Inc, and Paratek Pharmaceuticals.
Currently, the analyst consensus on Teva Pharma is a Hold with an average price target of $22.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $33.39 and a one-year low of $10.85. Currently, Teva Pharma has an average volume of 11.31M.
Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TEVA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company, which engages in development, production and marketing of drugs, generic drugs, over-the-counter drugs, active ingredients for the pharmaceutical industry (APIs) and therapeutic products. It operates through two segments: Generic Medicines and Specialty Medicines.
Read More on TEVA:
